Alliance Pharma Dividends - APH

Alliance Pharma Dividends - APH

[ADVERT]
Best deals to access real time data!
Silver
Monthly Subscription
for only
£17.37
Level 2 Basic
Monthly Subscription
for only
£62.08
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type
Alliance Pharma Plc APH London Ordinary Share
  Price Change Price Change % Stock Price Last Trade
0.00 0.0% 102.00 00:00:00
Open Price Low Price High Price Close Price Previous Close
102.00
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Alliance Pharma APH Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
21/09/2021InterimGBX0.5631/12/202031/12/202123/12/202124/12/202107/01/20220
23/03/2021FinalGBX1.0831/12/201931/12/202010/06/202111/06/202108/07/20211.61
22/09/2020InterimGBX0.5331/12/201931/12/202017/12/202018/12/202007/01/20210
24/09/2019InterimGBX0.5431/12/201831/12/201919/12/201920/12/201910/01/20200.54
26/03/2019FinalGBX0.9831/12/201731/12/201813/06/201914/06/201911/07/20191.47
19/09/2018InterimGBX0.48731/12/201731/12/201820/12/201821/12/201810/01/20190
27/03/2018FinalGBX0.8931/12/201631/12/201714/06/201815/06/201811/07/20181.33
13/09/2017InterimGBX0.4431/12/201631/12/201721/12/201722/12/201711/01/20180
29/03/2017FinalGBX0.80731/12/201531/12/201615/06/201716/06/201712/07/20171.21
14/09/2016InterimGBX0.40331/12/201531/12/201622/12/201623/12/201612/01/20170
07/04/2016FinalGBX0.7431/12/201431/12/201516/06/201617/06/201613/07/20161.1
09/09/2015InterimGBX0.3631/12/201431/12/201524/12/201529/12/201514/01/20160
25/03/2015FinalGBX0.6731/12/201331/12/201418/06/201519/06/201515/07/20151
10/09/2014InterimGBX0.33331/12/201331/12/201403/12/201405/12/201415/01/20150
26/03/2014FinalGBX0.6131/12/201231/12/201311/06/201413/06/201410/07/20140.91
11/09/2013InterimGBX0.30331/12/201231/12/201304/12/201306/12/201315/01/20140
21/03/2013FinalGBX0.5531/12/201131/12/201212/06/201314/06/201311/07/20130.83
12/09/2012InterimGBX0.27531/12/201131/12/201205/12/201207/12/201215/01/20130
22/03/2012FinalGBX0.531/12/201031/12/201113/06/201215/06/201212/07/20120.75
07/09/2011InterimGBX0.2531/12/201031/12/201130/11/201102/12/201113/01/20120
23/03/2011FinalGBX0.431/12/200931/12/201015/06/201117/06/201114/07/20110.57
08/09/2010InterimGBX0.1731/12/200931/12/201001/12/201003/12/201014/01/20110
24/03/2010FinalGBX0.2331/12/200831/12/200916/06/201018/06/201015/07/20100.3
09/09/2009InterimGBX0.0730/12/200830/06/200902/12/200904/12/200915/01/20100

Top Dividend Posts

DateSubject
26/11/2021
13:16
km18: From WealthOracleAM... The company we cover today is a very particular business, as it brings expertise to the marketing and regulatory management of products, ensuring it reaches a wide range of people. Alliance is a UK-based specialty pharmaceutical company. They are neither a manufacturer, nor a proper pharmaceuticals developer. This allows them to run an asset-light business (without all of the warehousing and logistics) and keep their focus on the areas of the business where they are experts. A simpler way to describe them would be a retailer for healthcare products. Acquisitions are a rare sight, with one done last year (Biogix) and the previous in 2012, resulting in a low goodwill figure. Fundamentals look healthy. Revenue CAGR is currently at 21.8%. The one-off drop in EPS from last year is mainly due to non-cash impairment and amortisation charges and the acquisition costs relating to Biogix transaction. This also pushed the ROCE down to 3.41%, but the ratio is rising by a CAGR of 7.99%. Free cash flow was strong supported by favourable movements in working capital and the total dividend was significantly ahead of 2019. https://wealthoracle.co.uk/detailed-result-full/APH/153
21/9/2021
15:16
wad collector: This BB is humming with excitement ever since I acquired some in March. Usually shares drop when I buy them and the BB gets busy. I like this. Though won't buy much with the dividend. Interim results for the six months ended 30 June 2021 Strong growth from Consumer Healthcare brands and integration of Amberen complete Full year outlook in line with market expectations Alliance Pharma plc (AIM: APH), the international healthcare group, announces its interim results for the six months ended 30 June 2021 (the "Period"). HIGHLIGHTS -- The Group traded strongly in the Period with an excellent performance from Kelo-cote(TM), an uplift in revenue from Prescription Medicines and a significant contribution from recently acquired Amberen(TM) -- See-through revenue in total up 24% (+28% on a constant currency basis ("CCY")) to GBP80.9m; like-for-like ("LFL") see-through revenue, which excludes Amberen, up 9% (+12% CCY); statutory revenue up 27% to GBP78.6m (H1 2020 GBP61.7m) o Strong performance from Consumer Healthcare brands, with see-through revenue up 30% overall (+35% CCY) -- Kelo-cote revenue up 54% (+62% CCY) -- LFL Consumer Healthcare revenue up 8% (+12% CCY) o Prescription Medicines revenue up 12% (+12% CCY) -- Underlying gross margin up 4.7 % to 63.8% of see-through revenue (H1 2020: 59.1%), reflecting favourable changes in product mix; statutory gross margin up 3.1% to 65.6% (H1 2020: 62.5%) -- Underlying profit before tax up 24% to GBP20.1m (H1 2020: GBP16.3m); reported profit before tax GBP16.5m (H1 2020: GBP0.6m) -- Free cash flow GBP6.5m (H1 2020: GBP10.5m), reflecting the expected reversal of favourable working capital movements in Q4 2020 and the timing of sales within the Period -- Leverage reduced to 2.21 times from 2.43 times at December 2020 and expected to fall below 2.0 times by the end of the year -- Amberen integration complete and trading in line with management expectations -- Interim dividend payment of 0.563p, up 5% (interim dividend 2020: 0.536p)
23/3/2021
08:39
2vdm: The recorded webcast will also be made available at the investor section of Alliance's website, hxxps://www.alliancepharmaceuticals.com/investors/
18/2/2021
09:52
2vdm: RNSthis a.m.: Alliance Pharma plc (AIM: APH), the international healthcare group, will announce its results for the 12 months ended 31 December 2020 on Tuesday 23 March 2021. A conference call for analysts will be held at 10.30am on 23 March 2021; analysts who require dial-in details, please contact Buchanan at alliancepharma@buchanan.uk.com. A recorded webcast of the analyst conference call, including investor presentation slides, will be made available during the afternoon of 23 March 2021 at this link: hxxps://webcasting.buchanan.uk.com/broadcast/60180f8da6bfbf43d06ac2ea The recorded webcast will also be made available at the investor section of Alliance's website, hxxps://www.alliancepharmaceuticals.com/investors/. For more information, please contact Buchanan on 020 7466 5000 or email alliancepharma@buchanan.uk.com.
04/1/2021
23:27
thewheeliedealer: Hi all, My mate Peter @Conkers3 and myself did a ‘Twin Petes Investing’ Podcast a few days ago and part of our discussion includes APH and some others with a similar business model. We also chatted about loads of other Stocks and Ideas for research and a fair bit of educational stuff with regards to Investing and Portfolio Management. Anyway, if you use Youtube, Apple, Audioboom, Overcast or Spotify you can find it under the 'Conkers Corner' Channel (you want Podcast TPI 39) and you can find it on Soundcloud at the link below. I hope you enjoy it and find it useful, we try to keep them light and they are totally unscripted, not like all the stuffy financial fodder you are probably more used to !! Happy New Lockdown !! WD @wheeliedealer hTTps://soundcloud.com/user-479955511/conkers3-wheeliedealer-39-2064-profit-aph-clin-merc-pdd-axs-som-itm-adm-swg-vle-ai
29/12/2020
22:40
wba1: Interesting acquisition. I have held this share for a few years, having bought in the low 40s. I originally bought as the business model bears some resemblance (although more OTC focused) to Galen, a company which made me very good profits in the early 2000s. And the more I see of APH the more it behaves like Galen - low risk, throws off free cash flow reliably and makes few mistakes in its dealings. I suspect this deal will be the last until 2022 and I may look to slice some profit if it tops 100p.
25/9/2020
06:50
2vdm: Also reduced my holdings substantially. I've done very well out of APH and still hold, but I can't see it going anywhere at the moment, although I may re-visit when we have more news
22/9/2020
16:44
winnings1: AMUNRO- What stock did you buy to replace APH, did it work out o.k. for you?
22/9/2020
08:54
amunro: Tesla is an interesting one. Are they are a car maker or innovator of next gen technology like self driving cars and batteries? As an investor sometimes you just need to follow the market, make money, with the view to getting out when things dive. Its all about managing risk. I got out of APH as I want the money to grow faster than APH offers.
09/4/2020
10:05
scillyfool: 2vdm, I'm sure APH have their eyes on prospective struggling competitors, but as the integration of Nizoral won't be completed uhtil June I just thought that they should concentrate on getting that integrated before taking on further acquisitions. My own thoughts are that in future many previous company development strategies may need to be rethought. First priority - survival. A company with no debt and a cash pile can better survive any market shocks and not only keep investors happy by continuing to pay dividends, but perhaps be even better placed to buy struggling competitors. Let's hope that after all this Covid-19 is over APH pay a special dividend to their loyal shareholders equal to the pulled final dividend to reassure us.
ADVFN Advertorial
Your Recent History
LSE
APH
Alliance P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211207 07:17:40